Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing giredestrant plus palbociclib to anastrozole plus palbociclib in untreated postmenopausal ER-positive, HER2-negative early breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Anastrozole (Anastrozole)
• Giredestrant (giredestrant)
• Palbociclib (palbociclib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Early Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-02-02